Research & Development
Autoimmune: Page 2
NfL IDs patients predisposed to neurotoxic complications
Analyzing blood samples from patients before, during, and after CAR-T cell therapy, Washington University School of Medicine researchers found that levels of neurofilament light chain (NfL) proteins are higher in patients who develop neurotoxic complications.
August 31, 2022
Week in Review: Room-temperature CRISPR, Roche T-cell test for COVID response, Qiagen monkeypox syndromic panel, and more
Dear LabPulse.com member,
August 17, 2022
3M divides health, oral care division into new business
Its new standalone healthcare business will focus on oral care, wound care, healthcare information technology, and biopharma filtration. The tax-free transaction is expected to close by the end of 2023. 3M's healthcare sector generated approximately $8.6 billion in sales in 2021, according to the company.
July 27, 2022
Drug test detects possibly toxic cannabis derivative
Breaking research showcased on Tuesday at AACC 2022 demonstrates that common drug testing methods can do just that.
July 26, 2022
Labcorp NfL test confirms neurodegenerative disease
The neurofilament light chain (NfL) blood test will allow doctors to identify and verify signs of neurodegenerative disease, enabling physicians to provide a more effective and efficient path to diagnosis and treatment for patients, the firm said.
July 12, 2022
Quest Diagnostics launches monkeypox virus testing
The service will be available nationwide, with the exception of New York state, where Quest anticipates it will be available later if the New York Department of Health approves the laboratory-developed test.
July 12, 2022
Exagen highlights lupus diagnosis study
The trial, called Complement Activation Products vs. Standard ANA Testing: Treatment Outcomes, Diagnosis, and Economic Impact in Systemic Lupus Erythematosus (CAPSTONE), utilized multiple external databases and nearly 50,000 patient tests conducted with either Avise or standard-of-care labs.
July 4, 2022
Roche, Nordic Bioscience partner on tissue disease markers
According to Nordic, the extracellular matrix markers it develops are essential for chronic diseases involving tissue fibrosis and inflammation, and the collaboration with Roche will facilitate better clinical decisions in drug development and patient selection for precision medicine.
June 15, 2022
DxTerity Diagnostics launches gene expression test for lupus
IFN-1 is a key biomarker and important indicator of lupus severity and prognosis, the firm said, adding that high IFN-1 levels are linked to increased risk of disease severity and development of lupus nephritis.
June 9, 2022
PathAI to present AI pathology studies at London liver congress
The presentation abstracts describe the use of a new machine learning-enabled continuous scoring system for nonalcoholic steatohepatitis (NASH), the firm said.
June 8, 2022
FDA clears Thermo Fisher autoimmune disease tests
The Waltham, MA-based firm said EliA RNA Pol III is the first fully automated RNA polymerase test for systemic sclerosis available in the U.S. Its EliA Rib-P test can be used to support the diagnosis of systemic lupus erythematosus, particularly in antinuclear antibody-negative patients.
June 8, 2022
Quotient, Theradiag to partner on autoimmune disease testing
Under the terms of their agreement, Theradiag will supply autoimmune reagents and multiconstituent quality controls for the development of autoimmune microarrays that will be used on the Quotient MosaiQ platform.
June 7, 2022
Page 2 of 9